LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Boston Scientific Corp.

Chiusa

SettoreSettore sanitario

57.61 1.02

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

57.41

Massimo

57.67

Metriche Chiave

By Trading Economics

Entrata

669M

1.3B

Vendite

-83M

5.2B

P/E

Media del settore

23.398

49.701

EPS

0.8

Margine di Profitto

25.774

Dipendenti

59,000

EBITDA

116M

1.1B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+51.66% upside

Dividendi

By Dow Jones

Utili prossimi

29 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-7.5B

83B

Apertura precedente

56.59

Chiusura precedente

57.61

Notizie sul Sentiment di mercato

By Acuity

26%

74%

59 / 345 Classifica in Healthcare

Boston Scientific Corp. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mag 2026, 11:04 UTC

Acquisizioni, Fusioni, Takeovers

Boston Scientific Buys 34% Stake in MiRus for $1.5 Billion

22 apr 2026, 11:22 UTC

Utili

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

4 feb 2026, 16:14 UTC

Utili
I principali Market Mover

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4 feb 2026, 12:13 UTC

Utili

Boston Scientific Sees More Growth after Earnings, Sales Rise

6 mag 2026, 20:15 UTC

Utili

Penumbra Not Be Providing Fincl Guidance Due to Pending Acquisition by Boston Scientific >PEN

6 mag 2026, 20:07 UTC

Utili

Penumbra 1Q Rev $374.8M >PEN

6 mag 2026, 20:07 UTC

Utili

Penumbra 1Q EPS 82c >PEN

22 apr 2026, 11:07 UTC

Utili

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adj EPS View

22 apr 2026, 10:32 UTC

Utili

Boston Scientific Now Sees 2026 Reported Sales Up 7%-8.5%, Organic Sales Up 6.5%-8% >BSX

22 apr 2026, 10:31 UTC

Utili

Boston Scientific Sees 2Q Reported Sales Up 5.5%-7.5%, Organic Sales Up 5%-7% >BSX

22 apr 2026, 10:30 UTC

Utili

Boston Scientific 1Q Organic Sales Up 9.4% >BSX

22 apr 2026, 10:30 UTC

Utili

Boston Scientific 1Q Adj EPS 80c >BSX

22 apr 2026, 10:30 UTC

Utili

Boston Scientific 1Q EPS 90c >BSX

22 apr 2026, 10:30 UTC

Utili

Boston Scientific 1Q Sales $5.2B >BSX

22 apr 2026, 10:30 UTC

Utili

Boston Scientific Sees 2Q Adj EPS 82c-Adj EPS 84c >BSX

22 apr 2026, 10:30 UTC

Utili

Boston Scientific Sees FY Adj EPS $3.34-Adj EPS $3.41 >BSX

30 mar 2026, 15:34 UTC

Discorsi di Mercato

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

4 feb 2026, 21:41 UTC

Utili

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 19:38 UTC

Utili

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 17:32 UTC

Utili

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4 feb 2026, 15:30 UTC

Utili

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4 feb 2026, 15:29 UTC

Utili

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4 feb 2026, 14:06 UTC

Utili

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4 feb 2026, 13:58 UTC

Utili

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 feb 2026, 13:12 UTC

Utili

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 feb 2026, 11:32 UTC

Utili

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4 feb 2026, 11:31 UTC

Utili

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4 feb 2026, 11:30 UTC

Utili

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4 feb 2026, 11:30 UTC

Utili

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4 feb 2026, 11:30 UTC

Utili

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

Confronto tra pari

Modifica del prezzo

Boston Scientific Corp. Previsione

Obiettivo di Prezzo

By TipRanks

51.66% in crescita

Previsioni per 12 mesi

Media 87.63 USD  51.66%

Alto 118 USD

Basso 68 USD

Basato su 27 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Boston Scientific Corp. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

27 ratings

26

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

59 / 345 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat